HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

First-line treatment of follicular lymphoma in the era of monoclonal antibodies.

Abstract
This review describes the recent evolution in the first-line treatment of patients with follicular lymphoma. In cases without adverse prognostic parameters, delayed treatment still is the best option. The combination of rituximab plus chemotherapy in patients with adverse prognostic parameters is the treatment associated with the highest complete response rates and the longer time to progression compared to chemotherapy or rituximab alone. The best chemotherapy regimen is not yet described. Also yet to be described is the place of radioimmunotherapy versus rituximab plus chemotherapy. High-dose therapies with autologous stem-cell transplant have a place in the treatment of these patients but not in first line.
AuthorsBertrand Coiffier
JournalClinical advances in hematology & oncology : H&O (Clin Adv Hematol Oncol) Vol. 3 Issue 6 Pg. 484-91, 505 (Jun 2005) ISSN: 1543-0790 [Print] United States
PMID16167027 (Publication Type: Comparative Study, Journal Article, Review)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab
Topics
  • Antibodies, Monoclonal (therapeutic use)
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Female
  • Humans
  • Lymphoma, Follicular (pathology, therapy)
  • Male
  • Radioimmunotherapy
  • Rituximab
  • Stem Cell Transplantation
  • Transplantation, Autologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: